The estimated Net Worth of Etienne Davignon is at least $98.1 Milione dollars as of 21 November 2013. Etienne Davignon owns over 9,778 units of Gilead Sciences stock worth over $93,905,455 and over the last 21 years Etienne sold GILD stock worth over $4,174,421.
Etienne has made over 7 trades of the Gilead Sciences stock since 2003, according to the Form 4 filled with the SEC. Most recently Etienne sold 9,778 units of GILD stock worth $699,811 on 21 November 2013.
The largest trade Etienne's ever made was exercising 100,000 units of Gilead Sciences stock on 3 October 2003 worth over $800,000. On average, Etienne trades about 6,759 units every 123 days since 2003. As of 21 November 2013 Etienne still owns at least 1,160,186 units of Gilead Sciences stock.
You can see the complete history of Etienne Davignon stock trades at the bottom of the page.
Etienne's mailing address filed with the SEC is SOCIETE GENERALE DE BELGIQUE, RUE ROYALE 30, BRUXELLES, C9, B-1000.
Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger e John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead Sciences executives and other stock owners filed with the SEC include: